The number of ESG regulations continues to grow. Leading medtech companies are going beyond merely complying to gain competitive advantage.
![jan-frederik-jerratsch-tcm9-201623.jpg](https://web-assets.bcg.com/dims4/default/caabe1a/2147483647/strip/true/crop/298x298+0+0/resize/500x500!/format/webp/quality/90/?url=http%3A%2F%2Fboston-consulting-group-brightspot.s3.amazonaws.com%2F78%2F45%2F5cbdfd267f28f4eec6ebd74c5739%2Fjan-frederik-jerratsch-tcm9-201623.jpg)
Education
- PhD, physics, Max-Planck-Society/Fritz-Haber Institute
- Diplom., physics, Humboldt University of Berlin
Jan-Frederik Jerratsch has been with Boston Consulting Group since 2011. He is a core member of the firm's Health Care practice and a specialist in life sciences, working with major high-tech, biopharma, and agribusiness clients globally.
Jan-Frederik focuses on major transformations with digitally enabled business models as well as new innovation approaches.